CytomX Therapeutics CTMX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's EBITDA?
- CytomX Therapeutics (CTMX) reported EBITDA of -$19.64M in Q1 2026.
- How has CytomX Therapeutics's EBITDA changed year-over-year?
- CytomX Therapeutics's EBITDA decreased by 186.7% year-over-year, from $22.66M to -$19.64M.
- What is the long-term trend for CytomX Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), CytomX Therapeutics's EBITDA has grown at a -33.8% compound annual growth rate (CAGR), from -$115.9M to -$22.22M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.